专利检索 ap:"Institut Recerca Hospital de la Santa Creu I Sant Pau" 第 1 页

1.

发明公开
PROTEIN NANO- OR MICROPARTICLES AS ARTIFICIAL INCLUSION BODIES 审中-公开

公开(公告)号：EP3953368A1

公开(公告)日：2022-02-16

申请号：EP20736248.4

申请日：2020-04-08

申请人： Universitat Autònoma de Barcelona , Institut Recerca Hospital de la Santa Creu I Sant Pau , Consorcio Centro de Investigación Biomédica en Red, M.P. (CIBER)

发明人： VILLAVERDE CORRALES, Antonio , VÁZQUEZ GÓMEZ, Esther , LÓPEZ LAGUNA, Héctor , SÁNCHEZ, Julieta María , MANGUES BAFALLUY, Ramón , ALAMO, Patricia

IPC分类号： C07K14/00 , B82Y5/00 , A61K38/00 , A61K47/00

2.

发明公开
COMBINATION PRODUCT FOR THE TREATMENT OF NEUROLOGICAL AND/OR PSYCHIATRIC DISORDERS 审中-公开

公开(公告)号：EP3713568A1

公开(公告)日：2020-09-30

申请号：EP18796407.7

申请日：2018-10-26

申请人： Consejo Superior de Investigaciones Científicas (CSIC) , Universidad Autónoma de Madrid , Centro De Investigacíon Biomédica En Red De Enfermedades Neurodegenerativas Ciberned , BlumenTech S.L. , Institut Recerca Hospital de la Santa Creu I Sant Pau

发明人： PEREZ CASTILLO, Ana María , RIBA SERRANO, Jordi , MORALES GARCÍA, Jose Ángel

IPC分类号： A61K31/4045 , A61K45/06 , A61P25/00

3.

发明公开
METHODS AND REAGENTS FOR EFFICIENT AND TARGETED DELIVERY OF THERAPEUTIC MOLECULES TO CXCR4 CELLS 有权
标题翻译：方法和试剂细胞CXCR4治疗性分子在高效，靶向给药

公开(公告)号：EP2663336A1

公开(公告)日：2013-11-20

申请号：EP12704711.6

申请日：2012-01-13

申请人： Universitat Autònoma De Barcelona , Institut Recerca Hospital de la Santa Creu i Sant Pau , Centro Investigación Biomédica en Red (Ciber BBN)

发明人： VILLAVERDE CORRALES, Antonio , VÁZQUEZ GÓMEZ, Esther , CÉSPEDES NAVARRO, María Virtudes , CASANOVA RIGAT, Isolda , FERRER MIRALLES, Neus , MANGUES BAFALLUY, Ramon , UNZUETA ELORZA, Ugutz

IPC分类号： A61K47/48 , C07K14/435 , C12N15/62

CPC分类号： A61K38/10 , A61K47/62 , A61K47/66 , C07K7/08 , C07K14/00 , C07K14/43504 , C12N15/62

摘要： The invention relates to conjugates comprising a targeting moiety specific for the CXCR4 based on the polyphemusin-derived peptide and a therapeutic or imaging agent. The invention relates as well to the application of said conjugates for the therapy and diagnostics which require the specific targeting to CXCR4+ cells.